Please see below for a list of search results.
Issued March 2010 Umbilical cord blood (cord blood) is collected at the time of birth and stored so that it may be available for potential future treatment of the child or another person.
In 2012 the HTA successfully negotiated with the EU Commission an amendment to the wording of the testing requirements for human T-lymphotropic virus (HTLV).
The Human Tissue Authority (HTA) welcomes the publication of the report from the Regenerative Medicine Expert Group, “Building on our own potential: a UK pathway for regenerative medicine”.
HTA-licensed establishments in the post mortem sector are required to report incidents (HTARIs), and those in the human application and organ donation and transplantation sectors are required to report serious adverse events or reactions (SAEARs), as part of their licensing with us.
Faecal microbiota transplants (FMT) are recognised as an emerging treatment for recurrent Clostridium difficile infections in patients where antibiotic and other lines of treatment have failed.
7 December 2015 update: The French Competent Authority issued an update to itsalert. The update noted that additional precautions taken in France following detection of this case of West Nile Virus in October 2015 were no longer in force.
Issued 27 November 2015
From the 4 January the HTA web Portal is open to collect annual activity data from organisations with an HTA human application licence. We are requesting data for the period covering 1 January to 31 December 2015.
This policy has been developed by the HTA in order to provide clarification and to assure consistency in the way licensed establishments apply the mandatory testing requirements for HTLV-1 testing.